Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Required: KMT2A (MLL) rearrangement

Required: NPM1 mutation

Must have received: intensive chemotherapy — relapsed/refractory

Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA/venetoclax

Must have received: hypomethylating agent — relapsed/refractory

Relapsed and primary refractory acute leukaemia after standard of care therapy including but not limited to 2 cycles of intensive chemotherapy, hypomethylating agent (HMA) monotherapy, or HMA combinations such as HMA/venetoclax

Must have received: hypomethylating agent — relapsed/refractory

Relapsed and primary refractory MDS is defined by ≥ 5% blasts in the bone marrow and/or persistence of peripheral blasts after treatment with at least 2 cycles of HMA

Cannot have received: menin inhibitor

Exception: backfill participants only

prior treatment other menin inhibitors (backfill participants only)

Cannot have received: investigational anticancer agent

Receipt of any investigational or non-investigational anticancer agents, including non-biologic agents, biologic agents

Cannot have received: non-investigational anticancer agent

Receipt of any non-investigational anticancer agents, including non-biologic agents and/or biologic agents

Cannot have received: radiation therapy

Exception: non-CNS radiation therapy within 2 weeks and CNS radiation within 8 weeks of the first scheduled dose

Receipt of non-CNS radiation therapy within 2 weeks and of CNS radiation within 8 weeks of the first scheduled dose

Cannot have received: radiation therapy

receipt of non-CNS or CNS radiation therapy